REFERENCES
1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019;69:184-210.
2. Sturgeon CM, Hoffman BR, Chan DW, Ch’ng SL, Hammond E, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54:e1-10.
3. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926-30.
4. Lai RC, Tan KH, Lim SK. Membrane lipid binding molecules for the isolation of bona fide extracellular vesicle types and associated biomarkers in liquid biopsy. J Cancer Metastasis Treat 2019;5:65.
5. Huang QQ, Chen XX, Jiang W, Jin SL, Wang XY, et al. Sensitive and specific detection of circulating tumor cells promotes precision medicine for cancer. J Cancer Metastasis Treat 2019;5:34.
6. Bookland MJ, Kolmakova A. Peripheral biomarkers for pediatric brain tumors: current advancements and future challenges. J Cancer Metastasis Treat 2019;5:33.
7. Farlow JL, Birkeland AC, Swiecicki PL, Brenner JC, Spector ME. Window of opportunity trials in head and neck cancer. J Cancer Metastasis Treat 2019;5:18.
8. Vander Borght A, Duysinx M, Ummelen M, van der Zeijst BAM. Monoclonal antibodies to the exon 18 encoded moiety of NCAM. J Cancer Metastasis Treat 2019;5:57.
9. Ossoliński K, Nizioł J, Arendowski A, Ossolińska A, Ossoliński T, et al. Mass spectrometry-based metabolomic profiling of prostate cancer - a pilot study. J Cancer Metastasis Treat 2019;5:1.
10. Zaichick V, Zaichick S. Levels of chemical element contents in thyroid as potential biomarkers for cancer diagnosis (a preliminary study). J Cancer Metastasis Treat 2018;4:60.
